Clinical Trial Update: A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma [Phase 3]

View source ↗

Summary

A Phase III randomized trial comparing the PD-1 inhibitor JS001 (toripalimab) to dacarbazine as first-line therapy for unresectable or metastatic melanoma has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Unresectable Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• JS001 (toripalimab) (toripalimab)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Metastatic Melanoma, Unresectable Melanoma | Phase 3 | Status: COMPLETED